Abstract
Obovatol derivatives were synthesized and evaluated for anti-platelet activity. Three derivatives (1, 2, 4i) displayed equipotent activity to obovatol in arachidonic acid-induced platelet aggregation. An initial SAR study revealed that the introduction of alkoxy group in B ring could enhance inhibitory activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cowan, D. H., Platelet adherence to collagen: Role of prostaglandin-thromboxane synthesis. Br. J. Haematol., 49, 425–434 (1981).
Eynard, A. R., Tremoli, E., Caruso, D., Magni, F., Sirtori, C. R., and Galli, G., Platelet formation of 12-hydroxyeicosatetraenoic acid and thromboxane B2 is increased in type IIA hypercholesterolemic subjects. Atherosclerosis, 60, 61–66 (1986).
Jackson, S. P. and Schoenwaelder, S. M., Antiplatelet therapy: in search of the ‘magic bullet’. Nat. Rev. Drug Discov., 2, 775–789 (2003).
Jin, Y. R., Im, J. H., Park, E. S., Cho, M. R., Han, X. H., Lee, J. J., Lim, Y., Kim, T. J., and Yun, Y. P., Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCγ2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity. J. Cardiovasc. Pharmacol., 51, 45–54 (2008).
Kwak, J. H., In, J. K., Lee, M. S., Yu, J. Y., Yun, Y. P., Hong, J. T., Lee, S. J., Seo, S. Y., Ahn, S. K., Suh, Y. G., Hwang, B. Y., Lee, H., Min, K. H., and Jung, J. K., Methyl aryloxy gallates as regulators of vascular smooth muscle cell proliferation. Bull. Korean Chem. Soc., 30, 2881–2882 (2009).
Lee, M. S., Yang, J. E., Choi, E. H., In, J. K., Lee, S. Y., Lee, H., Hong, J. T., Lee, H. W., Suh, Y. G., and Jung, J. K., Synthesis of obovatol derivatives and their preliminary evaluation as antitumor agents. Bull. Korean Chem. Soc., 28, 1601–1604 (2007).
Lee, S. Y., Cho, J. S., Yuk, D. Y., Moon, D. C., Jung, J. K., Yoo, H. S., Lee, Y. M., Han, S. B., Oh, K. W., and Hong, J. T., Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-κB. J. Pharmacol. Sci., 111, 124–136 (2009).
Lim, Y., Kwon, J. S., Kim, D. W., Lee, S. H., Park, R. K., Lee, J. J., Hong, J. T., Yoo, H. S., Kwon, B. M., and Yun, Y. P., Obovatol from Magnolia obovata inhibits vascular smooth muscle cell proliferation and intimal hyperplasia by inducing p21Cip1. Atherosclerosis, 210, 372–380 (2010).
Michelson, A. D., Antiplatelet therapies for the treatment of cardiovascular disease. Nat. Rev. Drug Discov., 9, 154–169 (2010).
Pollock, W. K., Rink, T. J., and Irvine, R. F., Liberation of [3H]arachidonic acid and changes in cytosolic free calcium in fura-2-loaded human platelets stimulated by ionomycin and collagen. Biochem. J., 235, 869–877 (1986).
Pyo, M. K., Lee, Y., and Yun-Choi, H. S., Anti-platelet effect of the constituents isolated from the barks and fruits of Magnolia obovata. Arch. Pharm. Res., 25, 325–328 (2002).
Willoughby, S., Holmes, A., and Loscalzo, J., Platelets and cardiovascular disease. Eur. J. Cardiovasc. Nurs., 1, 273–288 (2002).
Yu, J. Y., Lee, J. J., Jung, J. K., Kim, T. J., Yoo, H. S., Yun, Y. P., and Lee, J. C., JY0691, a newly synthesized obovatol derivative, inhibits cell cycle progression of rat aortic smooth muscle cells through up-regulation of p21(cip1). Eur. J. Pharmacol., 624, 23–30 (2009).
Author information
Authors and Affiliations
Corresponding authors
Additional information
These authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Kwak, JH., Lee, S., Park, ES. et al. Synthesis and anti-platelet activity of obovatol derivatives. Arch. Pharm. Res. 34, 1107–1112 (2011). https://doi.org/10.1007/s12272-011-0708-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-0708-9